## Xianglin L Du

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7238065/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Review of major adverse effects of androgenâ€deprivation therapy in men with prostate cancer. Cancer, 2009, 115, 2388-2399.	2.0	268
2	Impact of Enhanced Detection on the Increase in Thyroid Cancer Incidence in the United States: Review of Incidence Trends by Socioeconomic Status Within the Surveillance, Epidemiology, and End Results Registry, 1980–2008. Thyroid, 2013, 23, 103-110.	2.4	221
3	Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer, 2008, 113, 791-798.	2.0	219
4	Population-Based Assessment of Hospitalizations for Toxicity From Chemotherapy in Older Women With Breast Cancer. Journal of Clinical Oncology, 2002, 20, 4636-4642.	0.8	217
5	Racial disparity and socioeconomic status in association with survival in older men with local/regional stage prostate carcinoma. Cancer, 2006, 106, 1276-1285.	2.0	212
6	Patterns of Use of Chemotherapy for Breast Cancer in Older Women: Findings From Medicare Claims Data. Journal of Clinical Oncology, 2001, 19, 1455-1461.	0.8	188
7	Trends in Colorectal Cancer Incidence by Anatomic Site and Disease Stage in the United States From 1976 to 2005. American Journal of Clinical Oncology: Cancer Clinical Trials, 2011, 34, 573-580.	0.6	187
8	Racial disparities and socioeconomic status in association with survival in a large population-based cohort of elderly patients with colon cancer. Cancer, 2007, 110, 660-669.	2.0	157
9	Information on Radiation Treatment in Patients with Breast Cancer. Journal of Clinical Epidemiology, 1999, 52, 463-470.	2.4	152
10	Effects of individualâ€level socioeconomic factors on racial disparities in cancer treatment and survival. Cancer, 2011, 117, 3242-3251.	2.0	134
11	Racial disparities and treatment trends in a large cohort of elderly black and white patients with nonsmall cell lung cancer. Cancer, 2009, 115, 2199-2211.	2.0	114
12	Accuracy and Completeness of Medicare Claims Data for Surgical Treatment of Breast Cancer. Medical Care, 2000, 38, 719-727.	1.1	103
13	Racial disparities in colorectal cancer survival. Cancer, 2010, 116, 4622-4631.	2.0	102
14	Meta-analysis of racial disparities in survival in association with socioeconomic status among men and women with colon cancer. Cancer, 2007, 109, 2161-2170.	2.0	97
15	Impact of Treatment and Socioeconomic Status on Racial Disparities in Survival Among Older Women With Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 125-132.	0.6	93
16	Discrepancy between Consensus Recommendations and Actual Community Use of Adjuvant Chemotherapy in Women with Breast Cancer. Annals of Internal Medicine, 2003, 138, 90.	2.0	92
17	External Validation of Medicare Claims for Breast Cancer Chemotherapy Compared With Medical Chart Reviews. Medical Care, 2006, 44, 124-131.	1.1	91
18	Association Between Out-Of-Pocket Costs, Race/Ethnicity, and Adjuvant Endocrine Therapy Adherence Among Medicare Patients With Breast Cancer. Journal of Clinical Oncology, 2017, 35, 86-95.	0.8	90

#	Article	IF	CITATIONS
19	Ethnic variations in diagnosis, treatment, socioeconomic status, and survival in a large populationâ€based cohort of elderly patients with nonâ€Hodgkin lymphoma. Cancer, 2008, 113, 3231-3241.	2.0	83
20	Increase of chemotherapy use in older women with breast carcinoma from 1991 to 1996. Cancer, 2001, 92, 730-737.	2.0	70
21	Survival benefit of glioblastoma patients after FDA approval of temozolomide concomitant with radiation and bevacizumab: A population-based study. Oncotarget, 2017, 8, 44015-44031.	0.8	69
22	Cardiac toxicity associated with anthracyclineâ€containing chemotherapy in older women with breast cancer. Cancer, 2009, 115, 5296-5308.	2.0	67
23	Racial disparities in the use of hospice services according to geographic residence and socioeconomic status in an elderly cohort with nonsmall cell lung cancer. Cancer, 2011, 117, 1506-1515.	2.0	65
24	Competing Causes of Death for Women With Breast Cancer and Change Over Time From 1975 to 2003. American Journal of Clinical Oncology: Cancer Clinical Trials, 2008, 31, 105-116.	0.6	64
25	Socioeconomic status and cervical cancer survival among older women: Findings from the SEER–Medicare linked data cohorts. Gynecologic Oncology, 2006, 102, 278-284.	0.6	60
26	Racial and socioeconomic disparities in adjuvant chemotherapy for older women with lymph nodeâ€positive, operable breast cancer. Cancer, 2009, 115, 2999-3008.	2.0	57
27	Evaluation of trends in the use of intensityâ€modulated radiotherapy for head and neck cancer from 2000 through 2005. Cancer, 2010, 116, 3505-3512.	2.0	57
28	Chemotherapy use and risk of bone marrow suppression in a large population-based cohort of older women with breast and ovarian cancer. Medical Oncology, 2011, 28, 716-725.	1.2	50
29	Risks of Major Longâ€Term Side Effects Associated with Androgenâ€Deprivation Therapy in Men with Prostate Cancer. Pharmacotherapy, 2018, 38, 999-1009.	1.2	50
30	Variation in modes of chemotherapy administration for breast carcinoma and association with hospitalization for chemotherapy-related toxicity. Cancer, 2005, 104, 913-924.	2.0	48
31	Racial disparities and survival for nonsmall ell lung cancer in a large cohort of black and white elderly patients. Cancer, 2009, 115, 4807-4818.	2.0	47
32	Association of short-term increases in ambient air pollution and timing of initial asthma diagnosis among medicaid-enrolled children in a metropolitan area. Environmental Research, 2014, 131, 50-58.	3.7	47
33	Racial disparities in preoperative chemotherapy use in gastric cancer patients in the United States: Analysis of the National Cancer Data Base, 2006â€2014. Cancer, 2018, 124, 998-1007.	2.0	46
34	Assessing the initiation and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Medical Oncology, 2011, 28, 1062-1074.	1.2	45
35	Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998–2005. Medical Oncology, 2011, 28, 80-90.	1.2	45
36	Racial and Ethnic Disparities in Colorectal Cancer Screening Persisted Despite Expansion of Medicare's Screening Reimbursement. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 811-817.	1.1	45

#	Article	IF	CITATIONS
37	Racial/ethnic disparities in survival among men diagnosed with prostate cancer in Texas. Cancer, 2011, 117, 1080-1088.	2.0	44
38	Relationship Between Chemotherapy Use and Cognitive Impairments in Older Women With Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2010, 33, 533-543.	0.6	42
39	Racial/Ethnic Disparities in Socioeconomic Status, Diagnosis, Treatment and Survival among Medicare-insured Men and Women with Head and Neck Cancer. Journal of Health Care for the Poor and Underserved, 2010, 21, 913-930.	0.4	40
40	Improved survival of glioblastoma patients treated at academic and high-volume facilities: a hospital-based study from the National Cancer Database. Journal of Neurosurgery, 2020, 132, 491-502.	0.9	40
41	Information on chemotherapy and hormone therapy from tumor registry had moderate agreement with chart reviews. Journal of Clinical Epidemiology, 2006, 59, 53-60.	2.4	39
42	Risk of Chemotherapy-Induced Peripheral Neuropathy in Large Population-Based Cohorts of Elderly Patients With Breast, Ovarian, and Lung Cancer. American Journal of Therapeutics, 2010, 17, 148-158.	0.5	38
43	Chemotherapy-Associated Toxicity in a Large Cohort of Elderly Patients with Non-small Cell Lung Cancer. Journal of Thoracic Oncology, 2010, 5, 90-98.	0.5	38
44	Impact of Androgen Deprivation Therapy on Racial/Ethnic Disparities in the Survival of Older Men Treated for Locoregional Prostate Cancer. Cancer Control, 2009, 16, 176-185.	0.7	36
45	Survival of Women After Breast Conserving Surgery for Early Stage Breast Cancer. Breast Cancer Research and Treatment, 2002, 72, 23-31.	1.1	35
46	Elderly patients with non-Hodgkin lymphoma who receive chemotherapy are at higher risk for osteoporosis and fractures. Leukemia and Lymphoma, 2007, 48, 1514-1521.	0.6	35
47	Adherence to treatment guidelines and survival for older patients with stage II or III colon cancer in Texas from 2001 through 2011. Cancer, 2018, 124, 679-687.	2.0	35
48	Differences in treatment and survival among African-American and Caucasian women with early stage operable breast cancer. Ethnicity and Health, 2012, 17, 309-323.	1.5	33
49	Longâ€ŧerm survival after radical prostatectomy compared to other treatments in older men with local/regional prostate cancer. Journal of Surgical Oncology, 2008, 97, 583-591.	0.8	32
50	Trends and variations in mantle cell lymphoma incidence from 1995 to 2013: A comparative study between Texas and National SEER areas. Oncotarget, 2017, 8, 112516-112529.	0.8	32
51	Temporal and Geographic Variation in the Use of Hematopoietic Growth Factors in Older Women Receiving Breast Cancer Chemotherapy: Findings From a Large Population-Based Cohort. Journal of Clinical Oncology, 2005, 23, 8620-8628.	0.8	31
52	Ethnic Disparities in Cervical Cancer Survival Among Medicare Eligible Women in a Multiethnic Population. International Journal of Gynecological Cancer, 2009, 19, 13-20.	1.2	28
53	Impacts of cold weather on emergency hospital admission in Texas, 2004–2013. Environmental Research, 2019, 169, 139-146.	3.7	28
54	Menopausal Hormone Therapy and Lung Cancer-Specific Mortality Following Diagnosis: The California Teachers Study. PLoS ONE, 2014, 9, e103735.	1.1	27

#	Article	IF	CITATIONS
55	Racial Differences in Adjuvant Endocrine Therapy Use and Discontinuation in Association with Mortality among Medicare Breast Cancer Patients by Receptor Status. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 1266-1275.	1.1	27
56	Racial differences in long-term adjuvant endocrine therapy adherence and mortality among Medicaid-insured breast cancer patients in Texas: Findings from TCR-Medicaid linked data. BMC Cancer, 2018, 18, 1214.	1.1	26
57	Racial disparities and treatment trends in a large cohort of elderly African Americans and Caucasians with colorectal cancer, 1991 to 2002. Cancer, 2008, 113, 3400-3409.	2.0	25
58	The declining use of axillary dissection in patients with early stage breast cancer. Breast Cancer Research and Treatment, 1999, 53, 137-144.	1.1	24
59	Effectiveness of Adjuvant Chemotherapy for Node-Positive Operable Breast Cancer in Older Women. Journals of Gerontology - Series A Biological Sciences and Medical Sciences, 2005, 60, 1137-1144.	1.7	24
60	Geographic Variation and Sociodemographic Disparity in the Use of Oxaliplatin-Containing Chemotherapy in Patients With Stage III Colon Cancer. Clinical Colorectal Cancer, 2013, 12, 113-121.	1.0	23
61	Racial/ethnic differences in patient experiences with health care in association with earlier stage at breast cancer diagnosis: findings from the SEER-CAHPS data. Cancer Causes and Control, 2020, 31, 13-23.	0.8	23
62	Risks of developing breast and colorectal cancer in association with incomes and geographic locations in Texas: a retrospective cohort study. BMC Cancer, 2016, 16, 294.	1.1	22
63	Ethnic differences in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer enrolled in Medicare Part D. Medical Oncology, 2016, 33, 19.	1.2	20
64	Comparative Effectiveness of White Blood Cell Growth Factors on Neutropenia, Infection, and Survival in Older People with Nonâ€Hodgkin's Lymphoma Treated with Chemotherapy. Journal of the American Geriatrics Society, 2010, 58, 1885-1895.	1.3	19
65	Racial/Ethnic Differences in Treatment Discussed, Preferred, and Received for Prostate Cancer in a Tri-Ethnic Population. American Journal of Men's Health, 2012, 6, 249-257.	0.7	18
66	Cost-Effectiveness of Neoadjuvant Chemotherapy versus Primary Surgery in Elderly Patients with Advanced Ovarian Cancer. Value in Health, 2015, 18, 387-395.	0.1	18
67	Use of white blood cell growth factors and risk of acute myeloid leukemia or myelodysplastic syndrome among elderly patients with nonâ€Hodgkin lymphoma. Cancer, 2010, 116, 5279-5289.	2.0	17
68	Patterns of Treatment Sequences in Chemotherapy and Targeted Biologics for Metastatic Colorectal Cancer: Findings from a Large Community-Based Cohort of Elderly Patients. Drugs - Real World Outcomes, 2016, 3, 69-82.	0.7	17
69	Chemotherapy and Survival for Patients With Multiple Myeloma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 540-548.	0.6	16
70	Racial disparities in length of stay in hospice care by tumor stage in a large elderly cohort with non-small cell lung cancer. Palliative Medicine, 2012, 26, 61-71.	1.3	16
71	Association between chemotherapy and cognitive impairments in a large cohort of patients with colorectal cancer. International Journal of Oncology, 2013, 42, 2123-2133.	1.4	16
72	Cost Effectiveness of Chemotherapeutic Agents and Targeted Biologics in Ovarian Cancer: A Systematic Review. Pharmacoeconomics, 2015, 33, 1155-1185.	1.7	16

#	Article	IF	CITATIONS
73	Adjuvant Chemotherapy and Risk of Gastrointestinal, Hematologic, and Cardiac Toxicities in Elderly Patients With Stage III Colon Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2012, 35, 228-236.	0.6	15
74	Cost-Effectiveness of Novel Agents in Medicare Patients with Multiple Myeloma: Findings from a U.S. Payer's Perspective. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 831-843.	0.5	14
75	Association between financial burden and adjuvant hormonal therapy adherence and persistent use for privately insured women aged 18–64Âyears in BCBS of Texas. Breast Cancer Research and Treatment, 2018, 169, 573-586.	1.1	14
76	Swallowingâ€related outcomes associated with late lower cranial neuropathy in longâ€term oropharyngeal cancer survivors: crossâ€sectional survey analysis. Head and Neck, 2019, 41, 3880-3894.	0.9	14
77	Impact of facility type and volume in low-grade glioma outcomes. Journal of Neurosurgery, 2020, 133, 1313-1323.	0.9	14
78	Variations in Chemotherapy and Radiation Therapy in a Large Nationwide and Community-Based Cohort of Elderly Patients With Non-Hodgkin Lymphoma. American Journal of Clinical Oncology: Cancer Clinical Trials, 2007, 30, 163-171.	0.6	13
79	Clinical and Economic Outcomes Associated with Adjuvant Chemotherapy in Elderly Patients with Early Stage Operable Breast Cancer. Value in Health, 2012, 15, 72-80.	0.1	13
80	Relative impact of earlier diagnosis and improved treatment on survival for colorectal cancer: A US database study among elderly patients. Cancer Epidemiology, 2014, 38, 733-740.	0.8	13
81	Fracture risk prediction using FRAX in patients following hematopoietic stem cell transplantation. Archives of Osteoporosis, 2018, 13, 38.	1.0	13
82	Cost–Utility Analysis of Chemotherapy Regimens in Elderly Patients with StageÂIII Colon Cancer. Pharmacoeconomics, 2014, 32, 1005-1013.	1.7	11
83	Comparative Effectiveness of Chemotherapy Regimens in Prolonging Survival for Two Large Populationâ€Based Cohorts of Elderly Adults with Breast and Colon Cancer in 1992–2009. Journal of the American Geriatrics Society, 2015, 63, 1570-1582.	1.3	11
84	Geographic Variation in Oxaliplatin Chemotherapy and Survival in Patients With Colon Cancer. American Journal of Therapeutics, 2016, 23, e720-e729.	0.5	11
85	Temporal trends in the leading causes of death among a large national cohort of patients with colorectal cancer from 1975 to 2009 in the United States. Annals of Epidemiology, 2014, 24, 411-417.	0.9	10
86	Cost-Utility Analysis of Platinum-Based Chemotherapy versus Taxane and Other Regimens for Ovarian Cancer. Value in Health, 2014, 17, 34-42.	0.1	10
87	Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women. Value in Health, 2015, 18, 1070-1078.	0.1	10
88	Racial and geographic disparities in the patterns of care and costs at the end of life for patients with lung cancer in 2007–2010 after the 2006 introduction of bevacizumab. Lung Cancer, 2015, 90, 442-450.	0.9	10
89	Socio-demographic and geographic variations in the utilization of hormone therapy in older women with breast cancer after Medicare Part-D coverage. Medical Oncology, 2015, 32, 154.	1.2	10
90	Risk of Developing Alzheimer's Disease and Related Dementias in Association with Cardiovascular Disease, Stroke, Hypertension, and Diabetes in a Large Cohort of Women with Breast Cancer and with up to 26 Years of Follow-Up. Journal of Alzheimer's Disease, 2022, 87, 415-432.	1.2	10

#	Article	IF	CITATIONS
91	Racial and geographic disparities in adherence and discontinuation to adjuvant endocrine therapy in Texas Medicaid-insured patients with breast cancer. Medical Oncology, 2018, 35, 113.	1.2	9
92	Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes. Journal of Diabetes, 2019, 11, 684-689.	0.8	9
93	Risk and Clinical Risk Factors Associated With Late Lower Cranial Neuropathy in Long-term Oropharyngeal Squamous Cell Carcinoma Survivors. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 469.	1.2	9
94	Community-based Assessment of Adjuvant Hormone Therapy in Women with Breast Cancer, 1991-1997. Breast Journal, 2004, 10, 433-439.	0.4	8
95	Risk of Xerostomia in Association With the Receipt of Radiation Therapy in Older Patients With Head and Neck Cancer. American Journal of Therapeutics, 2011, 18, 206-215.	0.5	8
96	Impact of Hematopoietic Growth Factors on Blood Transfusion Needs, Incidence of Neutropenia, and Overall Survival Among Elderly Advanced Ovarian Cancer Patients Treated With Chemotherapy. International Journal of Gynecological Cancer, 2016, 26, 95-103.	1.2	8
97	Dietary Patterns and Hepatocellular Carcinoma Risk among US Adults. Nutrients, 2021, 13, 2011.	1.7	8
98	Comparative effectiveness of platinum-based chemotherapy versus taxane and other regimens for ovarian cancer. Medical Oncology, 2013, 30, 440.	1.2	7
99	Trends and variations in breast and colorectal cancer incidence from 1995 to 2011: A comparative study between Texas Cancer Registry and National Cancer Institute's Surveillance, Epidemiology and End Results data. International Journal of Oncology, 2015, 46, 1819-1826.	1.4	7
100	CMF-regimen Preferred as First-course Chemotherapy for Older and Sicker Women With Breast Cancer. American Journal of Clinical Oncology: Cancer Clinical Trials, 2015, 38, 165-173.	0.6	7
101	Associations between hematopoietic growth factors and risks of venous thromboembolism, stroke, ischemic heart disease and myelodysplastic syndrome: findings from a large population-based cohort of women with breast cancer. Cancer Causes and Control, 2016, 27, 695-707.	0.8	7
102	Improved survival in Medicare patients with multiple myeloma: findings from a large nationwide and population-based cohort. Medical Oncology, 2017, 34, 153.	1.2	7
103	Spatial Analysis of Industrial Benzene Emissions and Cancer Incidence Rates in Texas. International Journal of Environmental Research and Public Health, 2019, 16, 2627.	1.2	7
104	Ethnic Variations in Diagnosis, Treatment, Socioeconomic Status and Survival in a Large Population-Based Cohort of Elderly Patients with Non-Hodgkin's Lymphoma. Blood, 2008, 112, 2360-2360.	0.6	7
105	Racial disparities in health insurance, tripleâ€'negative breast cancer diagnosis, tumor stage, treatment and survival in a large nationwide SEER cohort in the United States. Molecular and Clinical Oncology, 2022, 16, 95.	0.4	7
106	Racial and ethnic disparities in the refusal of surgical treatment in women 40Âyears and older with breast cancer in the USA between 2010 and 2017. Breast Cancer Research and Treatment, 2022, 194, 643-661.	1.1	7
107	Cost-Effectiveness of Treatment Sequences of Chemotherapies and Targeted Biologics for Elderly Metastatic Colorectal Cancer Patients. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 64-73.	0.5	6
108	Racial, Socioeconomic, and Geographic Disparities in the Receipt, Timing to Initiation, and Duration of Adjuvant Androgen Deprivation Therapy in Men with Prostate Cancer. Journal of Racial and Ethnic Health Disparities, 2019, 6, 133-142.	1.8	6

#	Article	IF	CITATIONS
109	Risks of Venous Thromboembolism, Stroke, Heart Disease, and Myelodysplastic Syndrome Associated With Hematopoietic Growth Factors in a Large Population-Based Cohort of Patients With Colorectal Cancer. Clinical Colorectal Cancer, 2015, 14, e21-e31.	1.0	5
110	Use of Hematopoietic Growth Factors in Elderly Lung Cancer Patients Receiving Chemotherapy. American Journal of Clinical Oncology: Cancer Clinical Trials, 2017, 40, 66-74.	0.6	5
111	Risk of adverse events associated with front-line anti-myeloma treatment in Medicare patients with multiple myeloma. Annals of Hematology, 2018, 97, 851-863.	0.8	5
112	Increase in survival for patients with mantle cell lymphoma in the era of novel agents in 1995–2013: Findings from Texas and national SEER areas. Cancer Epidemiology, 2019, 58, 89-97.	0.8	5
113	Assessing the Optimum Use of Androgen-Deprivation Therapy in High-Risk Prostate Cancer Patients Undergoing External Beam Radiation Therapy. American Journal of Men's Health, 2017, 11, 73-81.	0.7	4
114	Cancer incidence and survival trends among infants in the United States from 1975 to 2014. Pediatric Blood and Cancer, 2021, 68, e28917.	0.8	4
115	Real-world evidence on survival, adverse events, and health care burden in Medicare patients with mantle cell lymphoma. Leukemia and Lymphoma, 2021, 62, 1325-1334.	0.6	4
116	Increasing utilization and predictors of hematopoietic growth factors in patients diagnosed with colorectal cancer: findings from a large national population-based cohort in the USA, 1992–2009. Medical Oncology, 2014, 31, 242.	1.2	3
117	Temporal and Geographic Variations in the Receipt of Colony-Stimulating Factors and Erythropoiesis-Stimulating Agents in a Large Retrospective Cohort of Older Women With Breast Cancer From 2000 to 2009. American Journal of Therapeutics, 2016, 23, e411-e421.	0.5	3
118	The risk and survival outcome of subsequent primary colorectal cancer after the first primary colorectal cancer: cases from 1973 to 2012. BMC Cancer, 2017, 17, 783.	1.1	3
119	Breast cancer incidence trends in Asian women aged 20 or older as compared to other ethnic women in the United States from 2000 to 2018 by time period, age and tumor stage. Cancer Epidemiology, 2022, 76, 102076.	0.8	3
120	Use of Hematopoietic Growth Factors and Risk of Thromboembolic and Pulmonary Toxicities in Elderly Patients with Advanced Ovarian Cancer. Women's Health Issues, 2016, 26, 574-583.	0.9	2
121	Developing Customizable Cancer Information Extraction Modules for Pathology Reports Using CLAMP. Studies in Health Technology and Informatics, 2019, 264, 1041-1045.	0.2	2
122	Age and Racial Disparities in the Utilization of Anticancer, Antihypertension, and Anti-diabetes Therapies, and in Mortality in a Large Population-Based Cohort of Older Women with Breast Cancer. Journal of Racial and Ethnic Health Disparities, 2023, 10, 446-461.	1.8	2
123	Effects of Posttrial Antihypertensive Drugs on Morbidity and Mortality: Findings from 15-Year Passive Follow-Up after ALLHAT Ended. International Journal of Hypertension, 2021, 2021, 1-15.	0.5	2
124	The role of androgen deprivation therapy on biochemical failure and distant metastasis in intermediate-risk prostate cancer: effects of radiation dose escalation. BMC Cancer, 2015, 15, 190.	1.1	1
125	Comparative Effectiveness of Chemotherapy, Rituximab, and Bendamustine in Medicare Beneficiaries With Mantle-Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2019, 19, e616-e623.	0.2	1
126	Risk of hospitalized and non-hospitalized gastrointestinal bleeding in ALLHAT trial participants receiving diuretic, ACE-inhibitor, or calcium-channel blocker. PLoS ONE, 2021, 16, e0260107.	1.1	1

#	Article	IF	CITATIONS
127	Response to the Editor. Annals of Epidemiology, 2014, 24, 790.	0.9	0
128	EPID-01. ASSOCIATIONS OF TIMING OF ADJUVANT THERAPIES, RADIATION FRACTIONS AND RADIATION DOSES WITH GLIOBLASTOMA SURVIVAL: A RETROSPECTIVE COHORT ANALYSIS USING THE NATIONAL CANCER DATABASE AND SEER-MEDICARE DATABASE. Neuro-Oncology, 2018, 20, vi80-vi80.	0.6	0
129	Racial/ethnic difference in initiation and timing of adjuvant endocrine therapy among older women with hormone receptor-positive breast cancer Journal of Clinical Oncology, 2016, 34, e18076-e18076.	0.8	0
130	Risk of Developing Alzheimer's Disease and Related Dementias in ALLHAT Trial Participants Receiving Diuretic, ACE-Inhibitor, or Calcium-Channel Blocker with 18 Years of Follow-Up , 2022, 12, .		0